NASDAQ OMX

FLIR Introduces 'Thermal by FLIR' Program and First Four Partners - ARSENZ, Casio, Panasonic, and TinkerForge

Dela

Partners to Integrate FLIR Thermal Sensors and Brand Products with 'Thermal by FLIR'

WILSONVILLE, Ore., Jan. 08, 2018 (GLOBE NEWSWIRE) -- FLIR Systems, Inc. (NASDAQ:FLIR) today announced the 'Thermal by FLIR(TM)' program designed for technology partners who use FLIR® thermal imaging sensors and its first four partners who will showcase their innovations in FLIR's booth at the Consumer Electronics Show (CES®) 2018. The booth will feature products from partners that integrate FLIR's microthermal imaging sensor, FLIR Lepton®, including ARSENZ, Casio, Panasonic, and TinkerForge.

Thermal by FLIR is a new cooperative product development and marketing program that supports original equipment manufacturers (OEMs) and product innovators who use FLIR thermal imaging sensors in their products. The program ensures that those OEMs that use genuine FLIR sensors can carry the Thermal by FLIR brand and receive additional product development and marketing support from FLIR to build and market their products.  

The first partner innovations under the Thermal by FLIR program include:   

  • ARSENZ ThermoGlass - A wearable augmented-reality device that mounts to glasses, the ThermoGlass allows the wearer to see a thermal image at a glance and operates hands-free.
  • Casio EX-FR10 - Demonstrating Casio's commitment to innovation, this proof-of-concept device is part of the EXILIM FR multi-camera family of digital cameras. The EX-FR10 separates the FLIR Lepton thermal sensor from the camera controls and screen to allow users to take thermal photos from a distance via Bluetooth.
  • Panasonic Thermal Sensor - A thermal imaging attachment for the rugged Toughpad FZ-M1, a Windows-based 7-inch tablet built for field service, construction, utility, and quality assurance workers, allows users to take thermal images on the go. The Toughpad FZ-M1 will be available in Japan in the first quarter of 2018, and in the United States and Europe later in 2018.
  • TinkerForge Thermal Imaging Bricklet -  TinkerForge is a system of electronic building blocks for professional product makers. The TinkerForge Thermal Imaging Bricklet with a FLIR Lepton sensor allows makers to quickly build concepts for any project that need non-contact temperature measurements.

"We're excited to announce a wave of innovative products and concepts from our partners under our Thermal by FLIR program," said James Cannon, President and CEO of FLIR. "Our goal with this program is to expand the use of thermal imaging sensors to more applications and areas. The Thermal by FLIR brand that appears on products indicates that the sensor installed is a genuine FLIR sensor and serves as a reminder to users that they are purchasing a device equipped with a thermal sensor from the world's leader."

The Thermal by FLIR program builds upon previous co-marketing agreements with Bullitt Group on the CAT S60 smartphone and DJI on the DJI Zenmuse XT, both of which included FLIR sensors and branding. The new Thermal by FLIR partner product innovations will be displayed at CES 2018 in the FLIR booth in the Las Vegas Convention Center, South Hall 3, #31160. FLIR is looking for the next innovative company to partner with in the Thermal by FLIR program. To learn more, visit http://www.flir.com/thermalbyflir.

About FLIR Systems, Inc.

Founded in 1978 and headquartered in Wilsonville, Oregon, FLIR Systems is a world-leading maker of sensor systems that enhance perception and heighten awareness, helping to save lives, improve productivity, and protect the environment. Through its nearly 3,500 employees, FLIR's vision is to be "The World's Sixth Sense" by leveraging thermal imaging and adjacent technologies to provide innovative, intelligent solutions for security and surveillance, environmental and condition monitoring, outdoor recreation, machine vision, navigation, and advanced threat detection. For more information, please visit  www.flir.com   and follow  @flir .

Forward-Looking Statements

The statements of opinion in this release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates, and projections about FLIR's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including risks and uncertainties discussed from time to time in FLIR's Securities and Exchange Commission filings and reports. Such forward-looking statements speak only as of the date on which they are made and FLIR does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release, or for changes made to this document by wire services or Internet service providers.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9f3287f9-d3bf-438c-8014-d51635adc454

Media Contact:
Tim McDowd
Phone: 503-498-3146
Email: tim.mcdowd@flir.com

Investor Relations: 
Shane Harrison
Phone: 503-498-3547
Email: shane.harrison@flir.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FLIR Systems, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30Pressmeddelande

LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma

Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15Pressmeddelande

BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio

Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05Pressmeddelande

WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public

Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00Pressmeddelande

OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to

Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29Pressmeddelande

ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern

Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum